View Older Stories View More Recent Stories

Aug 10, 2023 08:00AM UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
Aug 8, 2023 08:00AM The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Aug 2, 2023 05:00PM UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Jul 31, 2023 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 27, 2023 09:55AM UroGen Pharma (URGN) Announces $120 Million Private Placement of Ordinary Shares
Jul 27, 2023 09:55AM UroGen Announces $120 Million Private Placement of Ordinary Shares
Jul 27, 2023 09:50AM UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
Jul 25, 2023 04:14PM UroGen Pharma (URGN) Announces the Appointment of James Robinson to its Board of Directors
Jul 25, 2023 04:10PM UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
Jul 10, 2023 08:00AM Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
Jul 6, 2023 08:00AM UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
Jun 20, 2023 08:00AM Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
Jun 9, 2023 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2023 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
May 11, 2023 08:00AM UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 4, 2023 08:00AM UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
May 1, 2023 02:00PM UroGen Pharma (URGN) Reports First Study to Evaluate JELMYTO Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
May 1, 2023 02:00PM First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
Apr 30, 2023 08:00AM New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis  
Apr 25, 2023 08:00AM UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
Mar 16, 2023 08:00AM UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
Mar 9, 2023 04:00PM UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
Mar 6, 2023 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2023 04:00PM UroGen Pharma to Present at Upcoming Investor Conferences
Feb 15, 2023 09:06AM Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
Jan 11, 2023 08:00AM Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
Dec 19, 2022 08:00AM UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Dec 9, 2022 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 2, 2022 12:00PM UroGen Pharma (URGN) Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102
Dec 2, 2022 12:00PM UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermedia
Dec 2, 2022 06:58AM UroGen Pharma (URGN) Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®
Dec 1, 2022 07:00PM UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper T
Nov 21, 2022 04:00PM UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
Nov 14, 2022 08:06AM UroGen (URGN) Highlights New Real-World Safety Data Published in The British Journal of Urology International for JELMYTO
Nov 14, 2022 08:00AM UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used i
Nov 10, 2022 08:00AM UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Nov 9, 2022 08:04AM UroGen Pharma (URGN) Appoints Dan Wildman to its Board
Nov 9, 2022 08:00AM UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
Nov 3, 2022 08:00AM UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
Oct 11, 2022 08:00AM UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
Sep 28, 2022 08:00AM UroGen Pharma (URGN) Announces FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
Sep 28, 2022 08:00AM FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
Sep 12, 2022 08:00AM UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
Sep 9, 2022 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2022 04:00PM UroGen Pharma Announces Upcoming 2022 Conferences
Aug 11, 2022 08:00AM UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
Jul 27, 2022 08:00AM UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
Jun 3, 2022 08:00AM UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2022 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
May 16, 2022 02:50PM UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with
View More Recent Stories View Older Stories